FOLH1 and prostate carcinoma: 177Lu-PSMA-617 recently received FDA approval for phase II clinical trials in the U.S., (“First U.S. multi-center investigational clinical trial of 177Lu-PSMA-617 targeted radioligand therapy in metastatic castration resistant prostate cancer receives FDA clearance”.